<DOC>
	<DOCNO>NCT01490918</DOCNO>
	<brief_summary>Primary objective To evaluate efficacy Acarbose add top Metformin Sitagliptin combinedly administer subject type-II diabetes , along placebo . Secondary objective 1 . To compare Metformin-Sitagliptin combination Sitagliptin-Acarbose combination efficacy 2 . To evaluate 6-month efficacy Acarbose add top Metformin-Sitagliptin combination</brief_summary>
	<brief_title>Study Evaluate Efficacy Acarbose , Metformin , Sitagliptin Combination Treatment DM Patients</brief_title>
	<detailed_description>1 ) Primary Endpoint With change HbA1c measure baseline 16th week , descriptive statistic ( mean , standard deviation , median , minimum value , maximum value 95 % confidence interval ) work . HbA1c , measure baseline , include covariates , comparison make Group-1 Group-2 analysis covariance ( ANCOVA ) . 2 ) Secondary Endpoints 1 . Changes CGMS , mixed meal tolerance test ( active GLP-1 , total GLP-1 , GIP insulin ) oxidative stress marker ( 8-OHdG , nitro tyrosine CML ) Group-1 Group-2 : With value measure baseline 16th week , mean , standard deviation , median , minimum value maximum value calculate . To analyze difference two group , perform ANCOVA baseline value covariate . 2 . Changes HbA1c , FPG PPG Group-1 Group-2 : With value measure baseline , 16th week 24th week 16th week 24th week , mean , standard deviation , median , minimum value maximum value calculate . To analyze difference two group , perform ANCOVA baseline value covariate . 3 . Changes HbA1c , FPG PPG Group-1 Group-3 : With value measure baseline , 16th week 24th week 16th week 24th week , mean , standard deviation , median , minimum value maximum value calculate . To analyze difference two group , perform ANCOVA baseline value covariate . 4 . Changes SMBG Group-1 Group-2 Group-1 Group-3 : With value measure 4th week , 16th week 24th week 16th week 24th week , mean , standard deviation , median , minimum value maximum value calculate . To analyze difference two group , perform ANCOVA baseline value ( 4wk ) covariate . 5 . Changes 1,5-AG Group-1 Group-2 Group-1 Group-3 : With value measure 16th week , mean , standard deviation , median , minimum value maximum value calculate . To analyze difference two group , perform ANCOVA baseline value covariate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Subjects typeII diabetes mellitus ; 2 . Subjects age 20 80 ; 3 . Subjects whose HbA1c ratio 7.0 % 10.0 % ; 4 . Subjects take Metformin Sitagliptin least 12 week ; 5 . Subjects give explanation clinical study sign consent form . 1 . Subjects take drug likely affect blood glucose need take drug , e.g. , glucocorticoid ; 2 . Subjects severe renal disease ( men : Scr &gt; 1.5 / woman : Scr &gt; 1.4 ) ; 3 . Subjects severe liver disease whose AST ALT least 2.5 time high upper limit normal ( ULN ) ; 4 . Subjects case history lactic acidosis ; 5 . Subjects case history myocardial infarction unstable angina underwent coronary artery bypass graft 6 month screen test arrhythmia treat ; 6 . Subjects congestive heart failure treat ; 7 . Subjects fall New York Heart Association ( NYHA ) class III IV ; 8 . Subjects case history acute chronic metabolic acidosis include ketoacidosis ; 9 . Subjects pregnant period lactation ; 10 . Subjects diagnose malignant tumor within 5 year ; 11 . Subjects hypersensitive Metformin , Sitagliptin Acarbose ingredient ; 12 . Subjects inflammatory bowel diseases intestinal ulcer enterostenosis ( include Subjects vulnerable enterostenosis ) chronic enteric disease related digestion absorption whose symptom likely worsen due intestinal gas ; 13 . Subjects participate clinical study Subjects within 60 day study ( take investigational drug ) ; 14 . Subjects judge unfit study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Type-II diabetes mellitus</keyword>
	<keyword>Acarbose</keyword>
	<keyword>ACADEMIC</keyword>
</DOC>